Does LEUPROLIDE Cause Product packaging quantity issue? 523 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 523 reports of Product packaging quantity issue have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.7% of all adverse event reports for LEUPROLIDE.
523
Reports of Product packaging quantity issue with LEUPROLIDE
0.7%
of all LEUPROLIDE reports
0
Deaths
0
Hospitalizations
How Dangerous Is Product packaging quantity issue From LEUPROLIDE?
Of the 523 reports.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 523 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Product packaging quantity issue?
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
LIFITEGRAST (153)
Which LEUPROLIDE Alternatives Have Lower Product packaging quantity issue Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM